Published in Crit Rev Oncol Hematol on January 19, 2007
Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov (2011) 1.89
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood (2009) 1.25
Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol (2012) 1.17
Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology (2011) 0.97
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int (2010) 0.96
Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. J Mol Biol (2012) 0.96
The Structural Role of Antibody N-Glycosylation in Receptor Interactions. Structure (2015) 0.95
Antigenic modules in the N-terminal S1 region of the transmissible gastroenteritis virus spike protein. J Gen Virol (2011) 0.94
Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. MAbs (2012) 0.93
Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies. Leukemia (2013) 0.92
Opportunities to exploit non-neutralizing HIV-specific antibody activity. Curr HIV Res (2013) 0.91
Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity. Dermatol Res Pract (2010) 0.90
The emerging importance of α-L-fucose in human breast cancer: a review. Am J Transl Res (2011) 0.89
Critical role of effector macrophages in mediating CD4-dependent alloimmune injury of transplanted liver parenchymal cells. J Immunol (2008) 0.87
HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies. J Virol (2010) 0.85
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia (2014) 0.83
Impact of Glycosylation on Effector Functions of Therapeutic IgG. Pharmaceuticals (Basel) (2010) 0.81
Novel decapeptides that bind avidly and deliver radioisotope to colon cancer cells. PLoS One (2007) 0.81
LyGDI, a novel SHIP-interacting protein, is a negative regulator of FcγR-mediated phagocytosis. PLoS One (2011) 0.81
Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture. Protein Sci (2012) 0.80
Evaluation of FcγRIIIB-NA1/NA2 Polymorphism in Visceral Leishmaniasis. Iran Red Crescent Med J (2014) 0.78
Dependence of surface monoclonal antibody binding on dynamic changes in FcgammaRIIb expression. Immunology (2008) 0.75
"Antibodies in cancer treatment". Crit Rev Oncol Hematol (2007) 0.75
Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology (2012) 0.75
Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. Int J Pharm (2013) 0.75
T0001, a variant of TNFR2-Fc fusion protein, exhibits improved Fc effector functions through increased binding to membrane-bound TNFα. PLoS One (2017) 0.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.20
Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 2.37
The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res (2007) 2.34
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest (2010) 2.02
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology (2009) 2.01
Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res (2011) 1.91
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood (2010) 1.74
Natural immunity to cancer in humans. Curr Opin Immunol (2010) 1.69
Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res (2011) 1.63
Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res (2013) 1.54
Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med (2014) 1.39
CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol (2005) 1.37
Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res (2013) 1.33
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis (2010) 1.32
CD63 tetraspanin slows down cell migration and translocates to the endosomal-lysosomal-MIICs route after extracellular stimuli in human immature dendritic cells. Blood (2004) 1.30
Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells. J Biol Chem (2001) 1.27
Chemical heterogeneity in cell death: combined synchrotron IR and fluorescence microscopy studies of single apoptotic and necrotic cells. Biopolymers (2003) 1.23
CC chemokine ligand 18, an atopic dermatitis-associated and dendritic cell-derived chemokine, is regulated by staphylococcal products and allergen exposure. J Immunol (2004) 1.18
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol (2008) 1.16
Fc gamma receptors. Immunol Lett (2004) 1.09
The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol (2011) 1.09
The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med (2015) 1.02
Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease. Gastroenterology (2011) 1.00
Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells. PLoS One (2012) 0.98
Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol (2005) 0.98
Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol (2005) 0.96
Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett (2006) 0.95
A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol (2008) 0.94
CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas. Hum Pathol (2005) 0.92
Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J (2009) 0.92
CD16b associates with high-density, detergent-resistant membranes in human neutrophils. Biochem J (2006) 0.92
From mice to humans: developments in cancer immunoediting. J Clin Invest (2015) 0.90
Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel (2007) 0.88
IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer (2003) 0.87
Characterization of immune functions in TRAF4-deficient mice. Immunology (2008) 0.87
Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther (2013) 0.87
A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One (2011) 0.85
IL-23 and IL-12p70 production by monocytes and dendritic cells in primary HIV-1 infection. J Leukoc Biol (2010) 0.84
Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunol Immunother (2014) 0.84
A novel subset of NK cells expressing high levels of inhibitory FcgammaRIIB modulating antibody-dependent function. J Leukoc Biol (2008) 0.83
Effect of zinc on human IgG1 and its FcγR interactions. Immunol Lett (2012) 0.82
CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells. Vaccine (2011) 0.81
Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer Metastasis Rev (2011) 0.81
Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma. Pathol Oncol Res (2005) 0.81
High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function. Cancer Immunol Immunother (2012) 0.80
Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood (2004) 0.80
[Human lung cancer: role of TLR7 and TLR8 in cell survival and chemoresistance]. Med Sci (Paris) (2010) 0.80
Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins. J Clin Immunol (2014) 0.80
Activating and inhibitory Fcgamma receptors in immunotherapy: being the actor or being the target. Expert Rev Clin Immunol (2009) 0.78
Activation of human peripheral IgM+ B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB. J Immunol (2008) 0.78
Generation of murine scFv intrabodies from B-cell hybridomas. Methods Mol Biol (2002) 0.78
The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol (2011) 0.78
Apoptotic cell capture by DCs induces unexpectedly robust autologous CD4+ T-cell responses. Eur J Immunol (2014) 0.77
The immune microenvironments of lung and intraocular tumors. Bull Cancer (2011) 0.77
Monocyte-derived dendritic cells from HLA-B27+ axial spondyloarthritis (SpA) patients display altered functional capacity and deregulated gene expression. Arthritis Res Ther (2014) 0.77
1(st) French-Israeli International Conference on B Cells and therapeutic antibodies: October 23-25, 2011 Jerusalem, Israel. MAbs (2012) 0.75
L19. Lymphoid neogenesis in vascular chronic inflammation. Presse Med (2013) 0.75
Generation of scFv from a phage display mini-library derived from tumor-infiltrating B-cells. Methods Mol Biol (2002) 0.75
[EMABling antibodies: from feto-maternal allo-immunisation prophylaxis to chronic lymphocytic leukaemia therapy]. Med Sci (Paris) (2009) 0.75
[The 2010 years]. Med Sci (Paris) (2015) 0.75
[The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination]. Med Sci (Paris) (2013) 0.75
Generation of functional scFv intrabodies for triggering anti-tumor immunity. Methods (2004) 0.75
[Monoclonal antibodies: technology around the clock for new therapeutic hopes]. C R Biol (2006) 0.75
Dossier: auto-immunity and biotherapy. Biomed Pharmacother (2004) 0.75
[Antibodies: better knowledge for a better use]. Med Sci (Paris) (2009) 0.75
[About Ralph M. Steinman and dendritic cells]. Med Sci (Paris) (2011) 0.75
[Monoclonal antibodies, act two: new molecules for new challenges]. J Soc Biol (2006) 0.75